Neoplasms

Blood and Lymph Conditions

All Conditions

Hematologic Neoplasms

Hematologic Diseases

Antineoplastic Agents

All Drugs and Chemicals

Amino Acids

Trastuzumab

Pertuzumab

Atezolizumab

Trametinib

Dabrafenib

Alectinib

Pralsetinib

Entrectinib

Vemurafenib

Antineoplastic Agents, Immunological

Immune Checkpoint Inhibitors

Protein Kinase Inhibitors

Enzyme Inhibitors

Tyrosine Kinase Inhibitors

Tyrosine

For patients with a molecular tumor profile that can potentially be targeted by alectinib.

For patients with a molecular tumor profile that can potentially be targeted by cobimetinib.

For patients with a molecular tumor profile that can potentially be targeted by vismodegib.

For patients with a molecular tumor profile that can potentially be targeted by trastuzumab+pertuzuma combination.

For patients with a molecular tumor profile that can potentially be targeted by entrectinib.

For patients with a molecular tumor profile that can potentially be targeted by atezolizumab.

For patients with a molecular tumor profile that can potentially be targeted by vemurafenib.

For patients with a molecular tumor profile that can potentially be targeted by regorafenib.

For patients with a molecular tumor profile that can potentially be targeted by apalutamide.

For patients with a molecular tumor profile that can potentially be targeted by abemaciclib.

For patients with a molecular tumor profile that can potentially be targeted by selpercatinib.

For patients with a molecular tumor profile that can potentially be targeted by dabrafenib.

For patients with a molecular tumor profile that can potentially be targeted by trametinib.

For patients with a molecular tumor profile that can potentially be targeted by dabrafenib+trametinib combination.

For patients with a molecular tumor profile that can potentially be targeted by pralsetinib.

Cobimetinib

Vismodegib

Trastuzumab+Pertuzumab

Regorafenib

Apalutamide

Abemaciclib

Selpercatinib

Dabrafenib+Trametinib

Tanja Juslin

Katriina Jalkanen, MD, PhD

Erika Alanne, MD, PhD

Okko Kääriäinen, MD

Minna Tanner, MD, PhD

Katriina Peltola, MD, PhD

This is a prospective non-randomized national clinical phase 2 trial that aims to determine the efficacy and toxicity of targeted anticancer drugs or combinations that are approved or under review by EMA, FDA or PMDA and are used for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic, RNA-molecular or protein expression test.

This is a prospective non-randomized clinical trial that aims to determine the efficacy and toxicity of targeted anticancer drugs or combinations that are approved or under review by EMA, FDA or PMDA and are used for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic, RNA-molecular or protein expression test. The study also aims to facilitate patient access to approved targeted therapies that are contributed to the program by collaborating pharmaceutical companies and to perform next generation sequencing and further deeper analysis on tumor biopsies and/or liquid biopsies for biomarker analyses and resistance mechanisms. Eligible patients have an advanced cancer for which standard treatment options no longer exist and acceptable performance status and organ function. A tumour DNA, RNA or protein expression analysis is required and the results must identify at least one potentially actionable molecular variant as defined in the protocol. Molecular profiling will be utilized to determine an appropriate drug(s) from among those available in the protocol. Drug selection will be guided by a list of potential profiles, the molecular tumor board and databases of identified targets for review and approval of the recommended treatment. The protocol-specified treatment will be administered to the patient once any drug- and disease specific eligibility criteria and overall study criteria are met. Data for standard efficacy outcomes including tumor response, progression-free and overall survival as well as duration of treatment will be collected for all patients receiving treatment within the trial. In addition, treatment related toxicity will be collected according to CTCAE 5.0.

The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs

The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs to Determine the Efficacy in Treatment of Advanced Cancers With a Known Molecular Profile

Investigators plan to share the clinical study report.

Disease control rate at 16 weeks after treatment initiation (defined as patients by CR, PR, SD)

Treatment-related grade ≥3 and serious adverse events

Best overall response (defined as patients by CR, PR, SD)

Spots Global Cancer Trial Database for trastuzumab+pertuzumab